7 Giugno 2022
Craig Leonardi, Baojin Zhu, William N Malatestinic, William J Eastman, Jiaying Guo, Mwangi J Murage, Casey Kar-Chan Choong, Russel Burge, Andrew Blauvelt

Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: Results from IBM MarketScan® databases

Adv Ther. 2022 May 16. Online ahead of print
  • Obiettivo del presente studio è stato comparare la persistenza terapeutica di ixekizumab, in monoterapia o in associazione, rispetto agli altri biologici comunemente prescritti.
  • I pazienti trattati con ixekizumab hanno avuto una maggiore aderenza terapeutica e una più alta persistenza al trattamento, nonché un regime in monoterapia più lungo rispetto agli altri biologici.


Limited real-world data are available comparing multiple biologics on their adherence, persistence, and the use of concomitant biologics in the treatment of moderate-to-severe psoriasis in clinical practice. The objective was to compare persistence of and adherence to ixekizumab (IXE) treatment, as monotherapy or with concomitant medication, versus patients receiving other commonly prescribed biologics.

Patients who newly initiated IXE, adalimumab (ADA), etanercept (ETN), secukinumab (SEC), or ustekinumab (UST) in IBM MarketScan® databases with diagnosis of psoriasis were identified. Treatment comparisons on medication persistence, adherence, and monotherapy were based on balanced samples after inverse probability of treatment weighting (IPTW).

A higher proportion of patients receiving IXE had had previous biologic therapies (50.3%) versus other biologics (ADA: 9.1%, ETN: 10.9%, SEC: 33.9%, UST: 19.7%). Patients treated with IXE showed statistically (p <0.001) greater persistence than patients treated with SEC, ADA, UST, or ETN at both 1-year follow-up and up to 3 years of follow-up. Adherence for patients treated with IXE was significantly (p <0.001) higher compared to ADA, ETN, and UST at both 1-year follow-up and up to 3 years of follow-up. There was no significantly higher adherence in patients treated with IXE compared to those treated with SEC at 1-year follow-up, but IXE had higher adherence than SEC (p <0.05) at 1-3 year follow-up. IXE showed longer time on monotherapy than ADA (p <0.001), ETN (p <0.001), SEC (p <0.05), and UST (p <0.001) for both 1-year and 1-3 year follow-up. Sensitivity analyses on persistence, adherence, and monotherapy with further model adjustments after IPTW confirmed the findings.

Patients treated with IXE were more persistent on and adherent to treatment and remained on monotherapy longer compared to those on all other commonly prescribed biologics combined or with individual biologics.

Tagged on:
Scarica ppt Accedi all’abstract originale